# A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

> **NCT02413346** · PHASE3 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 490 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Sarecycline

## Key facts

- **NCT ID:** NCT02413346
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-20
- **Primary completion:** 2016-08-26
- **Final completion:** 2016-08-26
- **Target enrollment:** 490 (ACTUAL)
- **Last updated:** 2019-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413346, "A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02413346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*